Cardiff Oncology Inc Stock Price, News & Analysis

Cardiff Oncology (Nasdaq: CRDF) reported significant advancements in its clinical development of onvansertib for difficult-to-treat cancers, including KRAS-mutated colorectal cancer and pancreatic cancer, during Q2 2021. CEO Mark Erlander highlighted crucial milestones and leadership changes, including the appointment of a new CMO and CFO. The company initiated a Phase 2 trial for metastatic pancreatic cancer and presented positive data for its colorectal cancer program, indicating enhanced patient outcomes. Financially, Cardiff holds approximately $140 million in cash, with operating expenses rising to $7 million due to clinical activities.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced the appointments of Katherine L. Ruffner, M.D. as CMO and James E. Levine as CFO on July 12, 2021. Dr. Ruffner will lead clinical programs and pipeline expansion for onvansertib, aimed at treating cancers with critical medical needs. Mr. Levine will focus on financial strategy and business development. Both bring extensive experience in their fields, aligning with the company's growth strategy around upcoming clinical milestones. The Board approved stock options for the new executives as part of their inducement to join.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced that CEO Dr. Mark Erlander will participate in a fireside chat and virtual investor meetings at the William Blair Biotech Focus Conference 2021 on July 14-15, 2021. The chat is scheduled for July 15 from 12:00 – 12:45 PM ET. Cardiff is focused on developing onvansertib, a first-in-class Polo-like Kinase 1 (PLK1) inhibitor, targeting cancers with significant medical needs, including KRAS-mutated colorectal cancer and castrate-resistant prostate cancer. More details and a webcast link are available on their website.

Cardiff Oncology (Nasdaq: CRDF) has been added to the Russell 2000, Russell 3000, and Russell Microcap indexes effective June 28, 2021. This inclusion, part of the annual reconstitution, recognizes the company's market capitalization among the largest U.S. stocks as of May 7, 2021. Membership in these indexes provides increased visibility to institutional investors, as approximately $10.6 trillion in assets benchmark against Russell's indexes. Cardiff is focused on developing onvansertib for serious cancers, including KRAS-mutated colorectal and pancreatic cancers.

Cardiff Oncology (Nasdaq: CRDF) announced the appointment of Dr. Mani Mohindru and Dr. Renee P. Tannenbaum as independent board directors, replacing outgoing members Dr. Thomas Adams and Dr. Gary Jacob. This strategic move aims to enhance corporate governance and drive future growth. Dr. Mohindru brings extensive biotech leadership experience, while Dr. Tannenbaum adds expertise in business development and strategic partnerships. Both directors aim to advance the development of onvansertib, a drug targeting cancers with high medical need.

Cardiff Oncology (Nasdaq: CRDF) announced the first patient has been dosed in a Phase 2 trial of onvansertib, combined with nanoliposomal irinotecan and 5-FU, for metastatic pancreatic ductal adenocarcinoma (PDAC). This trial targets patients who failed prior gemcitabine therapy and aims to assess safety and preliminary efficacy across 40 patients at six U.S. sites. With PDAC's poor prognosis—7.7% response rate and 3.1-month median progression-free survival—onvansertib may improve treatment outcomes for those with KRAS mutations, prevalent in 95% of PDAC cases.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announces Dr. Mark Erlander will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The company focuses on developing onvansertib, a first-in-class Polo-like Kinase 1 inhibitor for challenging cancers such as KRAS-mutated colorectal cancer and pancreatic cancer. Dr. Erlander's presentation is scheduled for June 1 at 4:00 PM ET. A replay will be available on the Cardiff Oncology website post-event. The company aims to improve cancer treatment responses and overall patient survival using advanced biomarker technology.

Cardiff Oncology (Nasdaq: CRDF) reported a strong start to 2021, highlighted by progress in clinical trials involving onvansertib for treating KRAS-mutated cancers, including colorectal and pancreatic cancers. The company raised $20 million through a common stock sale to support clinical development. Recent data show promising outcomes, with a median progression-free survival of 9.4 months in a metastatic colorectal cancer trial, significantly better than historical controls. Operating expenses rose to $5.5 million, reflecting advancements in drug development and clinical activities.

Cardiff Oncology, Inc. (CRDF) announced positive results from its ongoing Phase 1b/2 trial of onvansertib for KRAS-mutated metastatic colorectal cancer (mCRC). The trial reported a 39% overall response rate, with a median progression-free survival (mPFS) of 9.4 months, significantly surpassing historical mPFS rates. The treatment showed good tolerability with no major toxicities. Biomarker analyses indicate the potential of plasma KRAS mutant allelic frequency in predicting patient response. Upcoming results from the Phase 2 trial are anticipated later this year.